Triangle Business Journal by Jason deBruyn, Staff Writer
Medical device company Bioptigen has received approval to market an eye-imaging tool in Europe.
Based in Research Triangle Park, Bioptigen focuses on devices to take detailed images of the eye. The company is a spinout from the Duke University Biomedical Engineering Department.
Sales projections were not publicly available. The company has raised about $7.5 million since 2005 through investors and grants. In a previous interview, Bioptigen President and CEO Eric Buckland said the private capital came primarily from angel investors.
“We are seeking to grow in the medical device space without the venture capital,” he said in November.
The approved device, the hand-held Envisu C2000-series, is intended for clinical use in the European Union.
